Liquidia (NASDAQ:LQDA) Price Target Raised to $111.00

Liquidia (NASDAQ:LQDA) had its price target raised by BTIG Research from $109.00 to $111.00 in a research report sent to investors on Wednesday,Benzinga reports. BTIG Research currently has a buy rating on the stock.

LQDA has been the topic of a number of other reports. Needham & Company LLC boosted their price objective on Liquidia from $70.00 to $110.00 and gave the company a “buy” rating in a research note on Wednesday. Oppenheimer set a $75.00 price objective on Liquidia in a research report on Friday, June 5th. Wells Fargo & Company upped their price target on shares of Liquidia from $51.00 to $62.00 and gave the company an “overweight” rating in a research report on Tuesday, May 12th. Jefferies Financial Group reiterated a “buy” rating and set a $60.00 price target on shares of Liquidia in a report on Monday, May 11th. Finally, HC Wainwright set a $36.00 price objective on Liquidia in a research report on Friday, July 24th. Two analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $98.08.

Liquidia Trading Up 3.2%

Shares of Liquidia stock opened at $74.44 on Wednesday. The company has a current ratio of 2.31, a quick ratio of 2.03 and a debt-to-equity ratio of 0.63. The stock has a fifty day simple moving average of $78.67 and a 200 day simple moving average of $55.13. Liquidia has a 12-month low of $21.15 and a 12-month high of $93.61. The company has a market capitalization of $6.62 billion, a P/E ratio of 54.34 and a beta of 0.58.

Liquidia (NASDAQ:LQDA) last announced its earnings results on Wednesday, August 12th. The company reported $0.74 earnings per share for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.02). The business had revenue of $171.68 million during the quarter, compared to analysts’ expectations of $168.48 million. Liquidia had a return on equity of 149.65% and a net margin of 30.74%.Liquidia’s quarterly revenue was up 1842.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.49) EPS. On average, sell-side analysts anticipate that Liquidia will post 2.74 earnings per share for the current fiscal year.

Insider Activity at Liquidia

In other Liquidia news, Director Paul B. Manning sold 200,000 shares of Liquidia stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $63.91, for a total value of $12,782,000.00. Following the completion of the sale, the director owned 716,311 shares of the company’s stock, valued at approximately $45,779,436.01. This trade represents a 21.83% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Stephen M. Bloch sold 242,269 shares of the company’s stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $70.43, for a total value of $17,063,005.67. Following the transaction, the director directly owned 1,176,184 shares in the company, valued at approximately $82,838,639.12. The trade was a 17.08% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 1,756,861 shares of company stock worth $122,981,112. Insiders own 25.60% of the company’s stock.

Hedge Funds Weigh In On Liquidia

Hedge funds and other institutional investors have recently bought and sold shares of the stock. TCG Crossover Management LLC purchased a new stake in shares of Liquidia during the 3rd quarter valued at about $38,887,000. MPM Bioimpact LLC boosted its holdings in Liquidia by 600.4% in the fourth quarter. MPM Bioimpact LLC now owns 1,400,869 shares of the company’s stock worth $48,316,000 after purchasing an additional 1,200,869 shares during the last quarter. Voloridge Investment Management LLC purchased a new stake in Liquidia during the 3rd quarter valued at $12,571,000. Bank of New York Mellon Corp bought a new position in shares of Liquidia during the 2nd quarter valued at $29,694,000. Finally, Bank of America Corp DE boosted its stake in shares of Liquidia by 18.7% in the 1st quarter. Bank of America Corp DE now owns 2,287,792 shares of the company’s stock worth $86,341,000 after buying an additional 360,372 shares during the last quarter. Institutional investors own 64.54% of the company’s stock.

More Liquidia News

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: YUTREPIA sales drove second-quarter revenue to $171.68 million, exceeding the $168.48 million consensus estimate, while revenue increased more than 1,800% year over year. Management also highlighted rising demand for the inhaled lung-disease treatment. LQDA Q2 Earnings Top
• Positive Sentiment: Liquidia is targeting more than $1 billion in 2027 net revenue as YUTREPIA gains market share and helps fund a broader inhaled-treprostinil pipeline, providing investors with a significant long-term growth narrative. LQDA Earnings Call Highlights
• Positive Sentiment: Bank of America raised its price target from $79 to $92, while BTIG Research and Needham indicated further appreciation potential. These targets support the bullish case, although Bank of America retained a neutral rating. Bank of America Price Target
• Neutral Sentiment: Lifesci Capital initiated or maintained a Market Perform view, reflecting more balanced expectations despite the company’s strong commercial momentum. Lifesci Capital Rating
• Negative Sentiment: Second-quarter adjusted earnings of $0.74 per share narrowly missed the $0.76 consensus estimate. The results triggered a negative reaction despite the revenue beat, particularly after LQDA had already risen sharply this year. Liquidia Shares Gap Down
• Negative Sentiment: HC Wainwright lowered its third-quarter 2026 EPS forecast to $1.01 from $1.15, adding pressure to near-term expectations. With a reported price-to-earnings ratio above 54, investors may be particularly sensitive to estimate reductions. HC Wainwright Estimate Revision

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).